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Background: In this study we performed genome-wide association studies to identify candidate SNPs that may
predict the risk of disease outcome in colorectal cancer.
Methods: Patient cohort consisted of 505 unrelated patients with Caucasian ancestry. Germline DNA samples were
genotyped using the Illumina® human Omni-1quad SNP chip. Associations of SNPs with overall and disease free
survivals were examined primarily for 431 patients with microsatellite instability-low (MSI-L) or stable (MSS) colorectal
tumors using Cox proportional hazards method adjusting for clinical covariates. Bootstrap method was applied for
internal validation of results. As exploratory analyses, association analyses for the colon (n = 334) and rectal (n = 171)
cancer patients were also performed.
Results: As a result, there was no SNP that reached the genomewide significance levels (p < 5x10−8) in any of the
analyses. A small number of genetic markers (n = 10) showed nominal associations (p <10−6) for MSS/MSI-L, colon, or
rectal cancer patient groups. These markers were located in two non-coding RNA genes or intergenic regions and none
were amino acid substituting polymorphisms. Bootstrap analysis for the MSS/MSI-L cohort data suggested the
robustness of the observed nominal associations.
Conclusions: Likely due to small number of patients, our study did not identify an acceptable level of association of
SNPs with outcome in MSS/MSI-L, colon, or rectal cancer patients. A number of SNPs with sub-optimal p-values were,
however, identified; these loci may be promising and examined in other larger-sized patient cohorts.
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One of the current interests of medicine is to first iden-
tify and then integrate new prognostic markers in pre-
diction models that can help distinguish cancer patients
with different risks of disease outcome after diagnosis.
Genetic sequence variations, such as single nucleotide
polymorphisms (SNPs), may have biological roles in
modifying the outcome risk and are the focus of the
many current prognostic studies. Among many genetic
approaches applied, the genomewide SNP survival* Correspondence: wxu@uhnresearch.ca; savas@mun.ca
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ine a large number of genetic markers scattered along
the DNA covering the majority of the genomic regions.
Several studies applied this approach to identify genetic
markers with prognostic associations in cancer such as pan-
creatic [1], esophageal [2], breast [3], and lung [4] cancers.
Colorectal cancer is a common malignancy [5]. Mor-
tality rates of this disease have been decreasing in many
countries including Asian [6], European [7], and North
American countries (Canada [8] and the USA [9]). Yet
even with this improvement in patient survival, the 5-
year survival rate for this disease is estimated to be 62-
64% in North America [10,11]. In other parts of the
world, such as in India and Eastern European countries,
these rates are lower [12]. In Canada, one of the highestis an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
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Newfoundland population [10]. This population is also
characterized by a high incidence of familial colorectal
cancer [13] and by one of the lowest cancer survival
rates in Canada [14].
The disease stage remains as the most important indi-
cator of prognosis of colorectal cancer patients. Research
reported in the literature suggests that other factors may
also modify the prognosis, such as age at diagnosis,
tumor location [15], vascular/lymphatic invasion [16],
and molecular features such as the microsatellite in-
stability (MSI) status [17,18].
MSI-high (MSI-H) is observed in almost 15% of the
colon cancers and is characterized by inactivation of DNA
mismatch repair genes either by germ line mutations in
MLH1, MSH2, MSH6, and PMS2 genes (inherited colon
cancer syndrome known as the Lynch syndrome; [19]) or
by the somatic promoter hypermethylation of the MLH1
gene (sporadic colorectal cancer with MSI-H [20]). Pa-
tients with the MSI-H tumors have better survival rates
than the patients with MSI-low (MSI-L) or microsatel-
lite stable (MSS) tumors and the chromosomal instabil-
ity (CIN) + tumors [17,18]. In addition, MSI-H tumor
phenotype is rarely observed in rectal cancers [21] and
colon and rectal cancers also differ from each other in
terms of other molecular alterations, risk of recurrence,
and treatment approaches [15,22,23].
Identification of genetic predictors of disease out-
comes in cancer patients is a promising research aim.
Till now, studies aiming to test the potential of polymor-
phisms as prognostic markers in colorectal cancer have
been restricted to the candidate gene or pathway ap-
proaches. In this study, for the first time we performed a
genomewide survival association study for patients with
MSS or MSI-L tumors (MSS/MSI-L; n = 431). In addition,
due to the differences between the colon and rectal cancers,
as an exploratory analysis we investigated the prognostic as-
sociations of the same genetic markers in the rectal (n =
171) and colon cancer (n = 334) patients separately.
Results
The baseline demographic, clinical and pathological data
for the patients in the MSS/MSI-L, colon, and rectal
cancer patient groups are shown in Table 1. The MSS/
MSI-L patient group was the largest (n = 431), followed
by colon (n = 334) and rectal (n = 171) patient groups.
The number of events for overall survival (i.e. death)
was 158, 105 and 65 in MSS/MSI-L, colon and rectal
groups and for disease free survival (i.e. recurrence, me-
tastasis or death) was 184, 121 and 79 in the same
groups, respectively. For the entire cohort (n = 505), the
5-year and 10-year survival probabilities were 79.0% and
46.4% for OS and the 5-year and 10-year disease-free
probabilities were 68.5% and 49.1%, respectively.The Quantile-Quantile (Q-Q) plots that were drawn
for each sub-group and each outcome are shown in the
Additional file 1. These plots show that the models on
the genome-wide scan satisfy the expected distribution
and suggest the appropriateness of the multivariate
model settings.
As a result of the statistical analysis, possibly due to
the limited sample size, no association with genome-
wide association significance levels (p < 5.0E-08) was de-
tected in models constructed. But, ten SNPs showed
suggestive associations with OS and DFS times (p <
1.0E-06), which is the nominal significance cut-off level
in our study (Table 2). Manhattan plots for the patient
cohorts and outcomes are shown in Additional file 1.
For the interested readers, the list of associations de-
tected at a p-value less than 1.0E-05 can be found in
Additional file 2.
In the MSS/MSI-L patient group association study,
there were two SNPs in the DFS model that achieved
the nominal-significance level (Table 2). The HRs ob-
tained as a result of the bootstrap method demonstrated
the robustness of the results from the original associ-
ation analysis (Additional file 3). One of these SNPs
(rs6720296) was a frequent variant (MAF: 40%) and
based on the information in the dbSNP database [24],
was located in a non-coding RNA gene (long intergenic
non-protein coding RNA 1121; LINC01121). The second
marker (rs1407508) was a relatively infrequent SNP
(MAF: 5.8%) located in a non-coding region on chromo-
some 9.
In the colon patient group analysis, two SNPs showed
nominally-significant signals in OS or DFS models
(Table 2). These SNPs were located in non-coding re-
gions along the chromosome 20 and 14.
Among all groups, the rectal cancer patient group was
the one with the largest group of SNPs identified, the
majority of which were intergenic. In this patient cohort,
two SNPs in OS model and four SNPs in DFS model
had p-value lower than the cut-off level (p < 1.0x10−6)
(Table 2). Interestingly, one intergenic SNP was associated
with both OS and DFS in this patient group (rs6854845).
Among the six SNPs, rs17057166 was the only one located
in a gene (non-coding RNA; AC011343.1).
None of the SNPs in Table 2 were amino acid chan-
ging SNPs (non-synonymous). As of February 2015,
there was no publication in PUBMED about these SNPs.
A search at the Regulome DB database [25] returned in-
formation for five of the polymorphisms (rs17026425,
rs1407508, rs17280262, rs17057166, and rs6854845). Ac-
cording to these results, rs17026425 (Regulome DB
score: 3a) is located within a transcription factor (such as
JUND) binding site, yet it is “relatively less likely to affect
protein binding”. For rs1407508 (Regulome DB score: 4),
rs17280262, rs17057166, and rs6854845 (Regulome DB
Table 1 Baseline characteristics of the MSS/MSI-L colorectal, colon and rectal cancer patients investigated in this study
Characteristics Entire cohort
(n = 505)
%* Colon cohort
(n = 334)
%* Rectal Cohort
(n = 171)
%* MSS/MSI-L cohort
(n = 431)
%*
Sex
Female 198 39 141 42 57 33 158 37
Male 307 61 193 58 114 67 273 63
Age at diagnosis (median) 61.4 years, range:
20.7-75
62.25 years,
range: 20.7-75
59.73 years,
range: 33.64-75
62.12 years,
range: 20.7-75
Histology
Non-mucinous 448 89 287 86 161 94 387 90
Mucinous 57 11 47 14 10 6 44 10
Location
Colon 334 66 334 100 0 0 274 64
Rectum 171 34 0 0 171 100 157 36
Stage
I 93 18 57 17 36 21 81 19
II 196 39 135 40 61 36 159 37
III 166 33 104 31 62 36 143 33
IV 50 10 38 11 12 7 48 11
Grade
Well/moderately differentiated 464 92 307 92 157 92 400 93
Poorly differentiated 37 7 24 7 13 8 27 6
Unknown 4 1 3 1 1 1 4 1
Vascular invasion
Absent 308 61 209 63 99 58 262 61
Present 159 31 107 32 52 30 137 32
Unknown 38 8 18 5 20 12 32 7
Lymphatic invasion
Absent 298 59 200 60 98 57 256 59
Present 167 33 112 34 55 32 144 33
Unknown 40 8 22 7 18 11 31 7
Familial risk
Low risk 250 50 161 48 89 52 218 51
High/moderate risk 255 50 173 52 82 48 213 49
MSI status
MSS/MSI-L 431 85 274 82 157 92 431 100
MSI-H 53 10 49 15 4 2 0 0
Unknown 21 4 11 3 10 6 0 0
BRAF Val600Glu mutation
Absent 411 81 263 79 148 87 377 87
Present 47 9 46 14 1 1 25 6
Unknown 47 9 25 7 22 13 29 7
Adjuvant chemotherapy status
Not given 224 44 174 52 50 29 189 44
Given 277 55 156 47 121 71 239 55
Unknown 4 1 4 1 0 0 3 1
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Table 1 Baseline characteristics of the MSS/MSI-L colorectal, colon and rectal cancer patients investigated in this study
(Continued)
Adjuvant 5-FU based
chemotherapy status
Not given 230 46 179 54 51 30 193 45
Given 261 52 147 44 114 67 226 52
Unknown 14 3 8 2 6 4 12 3
Adjuvant radiotherapy status
Not given 364 72 307 92 57 33 302 70
Given 124 25 11 3 113 66 113 26
Unknown 17 3 16 5 1 1 16 4
OS status
Alive 334 66 229 69 105 61 272 63
Dead 170 34 105 31 65 38 158 37
Unknown 1 0 0 0 1 1 1 0
OS time_2010 (median) 6.36 years,
range: 0.38-10.88
6.38 years,
range: 0.38-10.88
6.3 years,
range:1.64-10.65
6.32 years,
range: 0.38-10.88
DFS status
No recurrence,
metastasis or death
304 60 213 64 91 53 246 57
Recurrence, metastasis
or death
200 40 121 36 79 46 184 43
Unknown 1 0 0 0 1 1 1 0
DFS time (median) 6 years,
range: 0.22-10.88
6.22 years,
range: 0.38-10.88
5.48 years,
range:0.22-10.65
5.85 years,
range: 0.22-10.88
5-FU: 5-fluorouracil, DFS: disease-free survival, MSI-L: microsatellite instability-low, MSS: microsatellite stable, OS: overall survival. *numbers rounded.
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no evidence of proteins binding to the DNA sequences
where these SNPs are located.
An additional information related to the genes for the
SNPs with p-values less than 1.0x10−5 is shown in the
Additional file 4.Table 2 SNPs identified from six models with nominal signific
Group/Outcome Gene SNP Chr Position M
MSS/MSI-L-DFS LINC01121 rs6720296 2 45408269 0
MSS/MSI-L-DFS n/a (intergenic) rs1407508 9 101644538 0
colon-OS n/a (intergenic) rs4812219 20 59422971 0
colon-DFS n/a (intergenic) rs17280262 14 97053924 0
rectum-OS n/a (intergenic) rs17026425 4 150672514 0
rectum-OS n/a (intergenic) rs6854845 4 75746665 0
rectum-DFS n/a (intergenic) rs1570271 10 115288501 0
rectum-DFS AC011343.1 rs17057166 5 159248014 0
rectum-DFS n/a (intergenic) rs4868304 5 173131457 0
rectum-DFS n/a (intergenic) rs6854845 4 75746665 0
Chr: chromosome, CI_high: higher bound of the 95% confidence interval for the HR
DFS: disease-free survival, HWE-p: p-value for the Hardy-Weinberg Equilibrium test,
microsatellite instability-low, OS: overall survival, SNP: single nucleotide polymorphi
genetic markers, such as small insertions/deletions. For simplicity, all genetic marke
check the dbSNP database ([24]) for further information on these SNPs. Gene informDiscussion
In this study, we aimed to investigate the associations of
a large number of SNPs (n = 729,737) with overall or dis-
ease free survival times in Caucasian colorectal cancer
patients from Newfoundland, Canada. Our primary aim
was to investigate the associations of SNPs with theance (p < 1.0x10−6)
AF HWE-p genotype p-value HR CI_low CI_high
.4026 0.48 150 215 66 5.46E-07 1.74 1.40 2.16
.0580 0.65 383 46 2 8.51E-07 2.53 1.75 3.66
.0823 1.00 281 51 2 7.41E-07 3.27 2.05 5.23
.0629 0.13 295 36 3 1.33E-07 3.02 2.00 4.55
.0439 0.27 157 13 1 6.65E-07 5.06 2.67 9.60
.1082 0.70 135 35 1 9.46E-07 4.12 2.34 7.26
.0882 1.00 141 28 1 1.47E-07 3.66 2.26 5.94
.0468 1.00 155 16 0 2.11E-07 5.56 2.91 10.64
.1550 0.25 124 41 6 2.52E-07 2.91 1.94 4.37
.1082 0.70 135 35 1 6.16E-07 3.31 2.07 5.30
estimate, CI_low: lower bound of 95% confidence interval for the HR estimate;
HR: hazards ratio, MAF: minor allele frequency, MSS: microsatellite stable, MSI-L:
sm. Please note that the genotyping platform also contain other types of
rs are annotated as SNPs throughout this manuscript; interested readers may
ation as noted in the dbSNP database for each of the SNPs.
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mors (n = 431) as the outcome risks for this group of pa-
tients and the patients with the MSI-H tumors are
significantly different from each other [17,18]. In
addition, due to the differences between the colon and
rectal cancer patients (for example the relatively de-
creased recurrence risk as well as the higher number of
MSI-H tumors in colon cancer patients compared to the
rectal cancer patients [15,21]), as an exploratory analysis,
separate analyses for the colon (n = 334) and rectal (n =
171) cancer patients were also performed. Of note, due
to the small number of the patients with MSI-H tumors
(n = 53), we have not attempted the statistical analyses in
this group.
The main result of this study is that none of the gen-
etic markers investigated reached the genomewide sig-
nificance levels (5.0E-08) in either overall or disease
free survival analyses in any of the patient groups in-
vestigated. Thus, we were not able to identify a genetic
marker with a strong association with the risk of main
clinical outcomes (i.e. death, local or distant metasta-
ses) in colorectal cancer. This can be interpreted as that
none of the genetic markers investigated are related to
the survival outcomes of interest. Alternatively, this
can be also due to the fact that the sample sizes of the
patient cohorts investigated in this study were small
and thus our study power was limited to detect possible
associations (see Methods). Considering this study
power issue, in this manuscript we present and discuss
the SNPs with p-values (<1.0E-06) higher than the
genome-wide significance levels as potentially promis-
ing genetic markers (Table 2). We suggest that these
markers may be promising and should be investigated
in larger-sized cohorts to test whether they are associ-
ated with the colorectal cancer prognosis. Further re-
search may also be performed to test whether the two
non-coding RNA genes (AC011343.1 and LINC01121)
shown in Table 2 have prognostic roles in colorectal
cancer. In addition, while there is currently no litera-
ture report about the SNPs in Table 2 showing their
biological functions or relation to health and disease,
Regulome DB [25] data suggest that one of the SNPs,
rs17026425, is located within the binding site of JUN/
JUND transcription factors. Mammalian JUN family of
transcriptional regulators includes c-JUN, JUNB, and
JUND with important roles in cell proliferation and
carcinogenesis (reviewed in [26]). According to our re-
sults, rs17026425 polymorphism was nominally associ-
ated with overall survival in rectal cancer sub-group
(Table 2). Further studies on rs17026425 polymorphism
may test its potential binding to the JUN family of tran-
scription factors, its potential role in variable JUN func-
tion, and contribution to the rectal cancer formation
and progression.Conclusions
In conclusion, we performed genomewide SNP survival
association studies in MSS/MSI-L, colon and rectal cancer
patients. A limitation of this study is that all three patient
cohorts investigated were characterized by small samples
sizes, thus we cannot confidently conclude whether the in-
vestigated genetic markers indeed have no prognostic as-
sociations in colorectal cancer. However, this study also
generated a small set of SNPs that may be an interest for
other investigators in their future analyses.
Methods
Patient cohort
Patients registered at the Newfoundland Colorectal Can-
cer Registry (NFCCR) were investigated in the present
study. Characteristics of the NFCCR patient cohort were
described earlier [13,27]. Briefly, between 1999–2003, a
total of 750 participants were recruited to NFCCR. In-
formed consent was obtained from the patients or their
family members. Recurrence, metastasis or vital status
information for patients were collected till 2010 as de-
scribed in Negandhi et al. [28]. Tumor characteristics
(i.e. MSI status) were determined as explained by
Woods et al. [27]. Among 750 patients, 736 stage I-IV
patients had the prognostic data collected during the
follow-up period.
Genotyping and quality control (QC)
Germline DNA was isolated from patients’ blood samples.
Initially, a total of 539 patients with available prognostic
data and germline DNA were subject to whole-genome
SNP genotyping using the Illumina® Omni1-Quad human
SNP genotyping platform (service provider: Centrillion
Biosciences, USA).
QC analyses on the genetic data were performed using
PLINK v1.07 [29] and Eigensoft 4.2 [30]. We excluded 1)
one subject because of mismatching sex information; 2)
129,172 SNPs with high missing genotype data (above
5%); 3) 21 individuals who were first, second, or third
degree relatives (based on the identity by state PI_HAT
score >0.125), and 4) one subject with extreme value of
heterozygosity (out of 6 standard deviations). Addition-
ally, Multidimensional-scaling (MDS) method was used
to identify individuals with diversity in ancestry. Com-
paring with the Hapmap III points in the MDS plot, six
outliers that are far away from Caucasian cluster were
removed from the study (Additional file 5). Lastly,
275,285 SNPs and 320 SNPs were excluded because of
failure in HWE test (p < 1.0E-08) and low minor allele
frequency (MAF < 0.05), respectively.
Principal component analysis was undertaken with the
EIGENSTRAT package after QC filtering (Additional
file 5). The first two principal components were incorpo-
rated into the models. Additional analyses for population
Xu et al. Biomarker Research  (2015) 3:6 Page 6 of 7stratification were undertaken with each of the genetic
marker adjusting the estimated principal components. As
a result, five population outliers were identified and ex-
cluded from the analysis.
After these analyses, a total of 505 subjects and
729,737 SNPs were included in the final analysis. The
adequacy of the probability distribution and possibility
of differential genotyping were formally evaluated using
the Q-Q plots of –log10(p-values) (Additional file 1).Association analyses
We examined the associations of SNPs with two major
clinical outcomes: overall survival (OS) and disease free
survival (DFS). We define OS as the date from diagnosis
till the date of death from any cause or the date of last
follow-up, and DFS as the date from diagnosis till the
date of local recurrence, metastasis or death from any
cause, or the date of last follow-up. OS or DFS status
was available for 504 patients.
Cox proportional hazard models were applied based
on a genetic additive model. Hazard Ratio (HR) esti-
mates and corresponding 95% confidence intervals (CIs)
were calculated using R statistical programming lan-
guage [31]. The association between genetic markers
and survival outcomes, OS and DFS, adjusting for the
top two principal components and other confounding
factors (gender and stage for MSI-L or MSS sub-group,
gender, stage and MSI for colon and rectal sub-groups),
was tested using Cox proportional hazard model.
Clinical factors, as potential confounding factors in the
genetic analysis, were evaluated firstly using univariate
analysis. Among all the clinical factors: gender, stage,
MSI were found to be significantly associated with OS
(p-values: 0.0151, 2.2E-16, 5.2E-05, respectively); and
gender, site (colon/rectum), stage, MSI were shown to
be significantly associated with DFS (p-values: 0.0139,
0.0344, 3.3E-16, 1.2E-04, respectively). These clinical
variables were used to build up baseline multivariable
models for OS and DFS separately in each sub-cohort.
In order to present the genetic association with the
outcome variable in more detail, MSS/MSI-L patient,
colon cancer patients and rectal cancer patient groups
were analysed separately using Cox proportional haz-
ards model. Since two outcome measures (overall and
disease free survivals) were examined in MSS/MSI-L,
colon and rectum cancer patient cohorts, a total of six
models were constructed. While for the genome-wide
screening the genetic markers were modeled using addi-
tive genetic models, dominant, recessive, and co-
dominant genetic models were also applied as sensitivity
analysis to assess the genetic inheritance effect. For each
scenario, two types of models were explored, namely
crude, and comprehensive models: for the crude model,we adjusted by principal components only; for the com-
prehensive model, we adjusted by principal components
and the baseline model factors. In this report we show
the comprehensive models.
In order to validate the results obtained from the
MSS/MSI-L cohort association study, we applied boot-
strap resample method. Based on the original data set,
200 bootstrap samples data sets were generated using
sampling with replacement algorithm. For each of these
bootstrap data sets, we applied Cox proportional haz-
ards regression model on the SNPs with significance
levels p < 1.0x10−5 identified from the original analysis
and calculated the corresponding HRs of the genetic ef-
fect. Overall, 200 HRs were provided for each SNP and
bootstrap confidence intervals were created.
We computed the study power for the MSS-MSI-L
cohort (n = 431) using PASS 13 (NCSS, LLC. Kaysville,
Utah, USA). Assuming a SNP in linkage disequilib-
rium, LD, (D’ = 1) with a risk allele frequency 0.3, we
have 0.76 power to detect nominal significant associ-
ation at p < 1.0x10−6 under a dominant model with
strong effect size of HR 2.0 in the MSS-MSI-L cohort.
To detect an association with the same assumptions
and at p < 5E-08 significance level, the statistical power
is reduced to 0.56. With a moderate effect size of HR
1.5, the power to detect genome wide significant asso-
ciation (p < 5E-08) is very low (0.08).Additional files
Additional file 1: Q-Q and Manhattan plots. a) OS analysis in MSS/
MSI-L patient sub-cohort (Inflation factor: 1.024), b) DFS analysis in MSS/
MSI-L patient sub-cohort (Inflation factor: 0.971), c) OS analysis in colon
cancer patient sub-cohort (Inflation factor: 1.015), d) DFS analysis in colon
cancer patient sub-cohort (Inflation factor: 0.958), e) OS analysis in rectal
cancer patient sub-cohort (Inflation factor: 1.042), f) DFS analysis in rectal
cancer patient sub-cohort (Inflation factor: 1.005).
Additional file 2: SNPs identified from six models with significance
values of p < 10-5.
Additional file 3: Hazard ratios obtained by the bootstrap method
for the MSS/MSI-L patient cohort.
Additional file 4: Information on the genic locations of the genetic
polymorphisms with p < 1.0x10-5.
Additional file 5: Principal Component Analysis (PCA) and
Multidimensional Scaling (MDS) analysis results for the patient cohort.Abbreviations
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